Drug intelligence / Profile preview

AJA005

Development stage: Preclinical
Lead developer: AJNA
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules

Overview

AJA005 is an investigational drug candidate being developed by Ajna BioSciences for the treatment of sleep disorders. It is currently in the IND-enabling phase of development. The drug is classified as an undisclosed Schedule II controlled substance, which indicates it has a high potential for abuse but also has currently accepted medical use in treatment. As a product of Ajna BioSciences, a company specializing in standardized botanical drugs, AJA005 is likely a plant-derived compound or a synthetic derivative of a natural product. Specific details regarding its molecular target and mechanism of action have not been publicly disclosed.

Beyond the preview

Go deeper on AJA005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJA005.

Explore the full profile